Several approaches for anticancer drug development progress
نویسندگان
چکیده
Anticancer drug development is facing increasingly challenge. Much more chemicals or bio-agents are required to be evaluated every year. High-quality and speediness of evaluation requires joint-efforts between chemists pharmacologists. This Editorial provides this area anticancer discovery, licensing.
منابع مشابه
Lead Phytochemicals for Anticancer Drug Development
Cancer is a serious concern at present. A large number of patients die each year due to cancer illnesses in spite of several interventions available. Development of an effective and side effects lacking anticancer therapy is the trending research direction in healthcare pharmacy. Chemical entities present in plants proved to be very potential in this regard. Bioactive phytochemicals are prefere...
متن کاملMycotoxin- A Target for Anticancer Drug Development
The aim of this present article is to underscore the recent evidence linking anticancer activity and free radical scavenging activity of mycotoxins and its significance in the development of newer anticancer drugs. Although acute exposure to a massive amount of mycotoxin is rare but long-term exposure/consumption of food with low levels of lipophilic mycotoxin remains problematic. The aneuploid...
متن کاملDrug Development for Alzheimer's Disease: Recent Progress
Alzheimer's disease, the most common cause of dementia, is characterized by two major pathological hallmarks: amyloid plaques and neurofibrillary tangles. Based on these two indicators, an amyloid cascade hypothesis was proposed, and accordingly, most current therapeutic approaches are now focused on the removal of β-amyloid peptides (Aβ from the brain. Additionally, strategies for blocking tau...
متن کاملParallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
Current anticancer drug development still largely follows the classic designs developed for chemotherapeutic agents over the past 4 to 5 decades, remaining slow, costly, and inefficient, with continuing high risks of costly late drug attrition. A Pharmacologic Audit Trail has been described to decrease these risks, incorporating pharmacokinetic, pharmacodynamic, intermediate efficacy endpoints,...
متن کاملClinical development of imatinib: an anticancer drug
BACKGROUND A novel and accurate high-throughput tandem mass spectroscopic method has been developed and validated for determination of imatinib, a protein-tyrosine kinase inhibitor against chronic myeloid leukemia. MATERIALS & METHODS Chromatographic separation was carried on XTerra® RP18 column (150 mm × 4.6 mm, 5 µm particle size) manufactured by Waters Corporation, MA, USA. The detection w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nursing & care open access journal
سال: 2022
ISSN: ['2572-8474']
DOI: https://doi.org/10.15406/ncoaj.2022.08.00244